| 101 |
NCT01865110 |
Recruiting |
R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL |
|
- Drug: R-CHOP
- Drug: R-CHOP / R-HAD
- Drug: Rituximab
- Drug: Lenalidomide
|
Interventional |
Phase 3 |
- The Lymphoma Academic Research Organisation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival
|
633 |
All |
60 Years and older (Adult, Senior) |
NCT01865110 |
MCL R2 Elderly |
|
November 2013 |
June 2021 |
March 2024 |
May 30, 2013 |
March 7, 2018 |
|
- ZNA Stuivenberg
Antwerpen, Belgium - A. Z. Sint-Jan
Bruges, Belgium - Institut Jules Bordet
Bruxelles, Belgium - (and 137 more...)
|
| 102 |
NCT00730652 |
Withdrawn |
Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma |
- Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma.
|
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety Profile of MDX-1411 and determine the maximum tolerated dose (MTD)
|
34 |
All |
18 Years and older (Adult, Senior) |
NCT00730652 |
MDX1411-02 |
MDX1411-02 |
May 2009 |
December 2012 |
March 2013 |
August 8, 2008 |
April 22, 2010 |
|
|
| 103 |
NCT01073163 |
Completed
Has Results |
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) |
- Non-Hodgkin's Lymphoma
- Mantle Cell Lymphoma
|
- Drug: Bendamustine
- Drug: Rituximab
|
Interventional |
Phase 3 |
- Cephalon
- Teva Pharmaceutical Industries
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Mean Change From Baseline in QT Interval as Corrected by the Fridericia Method (QTcF) at End of Infusion
- Mean Change From Baseline in QTcF at 1 Hour Postinfusion
- Number of Participants With QTcF New Outlier Events at End of Infusion and 1 Hour Postinfusion
- (and 10 more...)
|
54 |
All |
18 Years and older (Adult, Senior) |
NCT01073163 |
C18083/3070 |
|
February 2010 |
June 2012 |
June 2012 |
February 23, 2010 |
April 24, 2014 |
April 4, 2014 |
- Hematology Oncology Physicans Extenders Group
Tucson, Arizona, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - St. Jude Heritage Medical Group
Fullerton, California, United States - (and 40 more...)
|
| 104 |
NCT02354313 |
Active, not recruiting |
Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients |
|
|
Interventional |
Phase 3 |
- Fondazione Italiana Linfomi ONLUS
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Overall Survival (OS)
- Disease-free survival (DFS)
- (and 5 more...)
|
300 |
All |
18 Years to 60 Years (Adult) |
NCT02354313 |
IIL-MCL0208
2009-012807-25 |
MCL0208 |
May 2010 |
December 2017 |
January 2019 |
February 3, 2015 |
February 9, 2018 |
|
- UO Ematologia Ospedale Dell'Angelo
Mestre, VE, Italy - SC Ematologia A.O.SS. Biagio e Antonio e C. Arrigo
Alessandria, Italy - AORN San G.Moscati
Avellino, Italy - (and 50 more...)
|
| 105 |
NCT01933711 |
Active, not recruiting |
Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma |
- CD20+ Aggressive Lymphoma, Mantle Cell Lymphoma
|
|
Interventional |
Phase 3 |
- University Hospital Heidelberg
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival
- time to progression (TTP)
- overall survival (OS)
- response to treatment
|
328 |
All |
18 Years and older (Adult, Senior) |
NCT01933711 |
HD2002 |
|
July 2002 |
December 2016 |
December 2018 |
September 2, 2013 |
May 13, 2016 |
|
- University of Heidelberg Hospital
Heidelberg, Baden-Württemberg, Germany - University of Mannheim Hospital
Mannheim, Baden-Württemberg, Germany - University of Bonn Hospital
Bonn, Nordhein-Westfalen, Germany
|
| 106 |
NCT02682641 |
Recruiting |
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL |
|
- Drug: IBRUTINIB
- Drug: Rituximab
|
Interventional |
Phase 2 |
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- Janssen-Cilag, S.A.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of complete remission
- Overall Response Rate (OR)
- Progression Free Survival
- (and 6 more...)
|
50 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT02682641 |
GELTAMO-IMCL-2015
2015-004158-17 |
|
May 2016 |
January 2020 |
January 2023 |
February 15, 2016 |
June 12, 2017 |
|
- Hospital Universitario Mútua Terrassa
Terrassa, Barcelona, Spain - Hospital Universitario Fundación Alcorcón
Alcorcón, Madrid, Spain - Hospital General Universitario Santa Lucía
Cartagena, Murcia, Spain - (and 12 more...)
|
| 107 |
NCT00877006 |
Completed
Has Results |
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study |
- Non-Hodgkin's Lymphoma
- Mantle Cell Lymphoma
|
- Drug: bendamustine
- Drug: rituximab
- Drug: vincristine
- (and 3 more...)
|
Interventional |
Phase 3 |
- Teva Branded Pharmaceutical Products, R&D Inc.
- Teva Pharmaceutical Industries
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Complete Response (CR) at End of Treatment Period
- Percentage of Participants With Overall Response at End of Treatment Period
- Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs at End of Treatment Period
- (and 14 more...)
|
447 |
All |
18 Years and older (Adult, Senior) |
NCT00877006 |
C18083/3064/NL/MN |
|
April 30, 2009 |
March 31, 2012 |
March 31, 2012 |
April 7, 2009 |
February 5, 2018 |
April 28, 2014 |
- Teva Investigational Site 165
Tucson, Arizona, United States - Teva Investigational Site 167
Little Rock, Arkansas, United States - Teva Investigational Site 11
Corona, California, United States - (and 125 more...)
|
| 108 |
NCT01449344 |
Active, not recruiting |
Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL |
|
- Drug: Rituximab
- Drug: High dose Ara-C
- Drug: Dexamethasone
- Drug: Bortezomib
|
Interventional |
Phase 3 |
- Prof. Dr. M. Dreyling (co-chairman)
- Klinikum der Universitaet Muenchen, Grosshadern
- ClinAssess GmbH
- (and 2 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from Baseline of diseased nodes and nodal masses.
|
128 |
All |
18 Years and older (Adult, Senior) |
NCT01449344 |
MCL2005-01 |
(R-HAD) |
May 9, 2009 |
December 2018 |
December 2018 |
October 10, 2011 |
March 7, 2017 |
|
- CH Victor Dupouy, Service hématologie
Argenteuil Cedex, France - Centre Hospitalier de la côte Basque, Service hématologie
Bayonne, France - CH de Blois, Service hématologie
Blois, France - (and 51 more...)
|
| 109 |
NCT02081937 |
Recruiting |
CART-19 Immunotherapy in Mantle Cell Lymphoma |
- Hematopoietic/Lymphoid Cancer
- Non-hodgkin Lymphoma,B Cell
- Mantle Cell Lymphoma
|
- Biological: anti-CD19-CAR vector-transduced T cells
|
Interventional |
Phase 1
Phase 2 |
- Chinese PLA General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Occurrence of study related adverse events
- Clinical responses to CART-19 cell therapy
|
2 |
All |
50 Years to 80 Years (Adult, Senior) |
NCT02081937 |
CN301-XYK-CAR001 |
|
March 2014 |
December 2018 |
December 2019 |
March 7, 2014 |
March 11, 2014 |
|
- Department of Hematology of Chinese PLA General Hospital
Beijing, Beijing, China
|
| 110 |
NCT02159755 |
Active, not recruiting |
Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma |
- CCND1 Positive
- Recurrent Mantle Cell Lymphoma
- t(11;14)
|
- Drug: Ibrutinib
- Other: Laboratory Biomarker Analysis
- Drug: Palbociclib
- Other: Pharmacological Study
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recommended phase II dose of the combination of ibrutinib and palbociclib defined as the highest dose level at which no more than 1/6 patients present with a dose limiting toxicity (DLT)
- Overall response rate (ORR)
- Complete response (CR) rate
- (and 4 more...)
|
28 |
All |
18 Years and older (Adult, Senior) |
NCT02159755 |
NCI-2014-01202
1403014853
9534
K24CA201524
P30CA013696
UM1CA186704
UM1CA186712 |
|
May 20, 2014 |
May 11, 2017 |
|
June 10, 2014 |
April 19, 2018 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States - Weill Medical College of Cornell University
New York, New York, United States - UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States - Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
|
| 111 |
NCT03311126 |
Recruiting |
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma |
- Mantle Cell Lymphoma
- Non-hodgkin Lymphoma
- Non Hodgkin Lymphoma
|
- Drug: Bendamustine
- Drug: Obinutuzumab
|
Interventional |
Phase 2 |
- University of Wisconsin, Madison
- Genentech, Inc.
- National Cancer Institute (NCI)
|
Other / Industry / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS) at 2 years
- Minimal Residual Disease (MRD) status
- Estimate the concordance rate between peripheral blood (PB) and bone marrow aspirates (BMA) in predicting MRD status.
- (and 3 more...)
|
32 |
All |
18 Years and older (Adult, Senior) |
NCT03311126 |
UW16086
P30CA014520
2017-0609
NCI-2017-01729 |
|
October 19, 2017 |
May 15, 2024 |
May 15, 2026 |
October 16, 2017 |
October 25, 2017 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
| 112 |
NCT01718691 |
Completed
Has Results |
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma |
- Low-grade B Cell Non-Hodgkin's Lymphoma
- Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated
|
- Drug: SyB L-0501
- Drug: rituximab
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC)
- Overall Response Rate (Antitumor Effect: PR or Better) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC)
- Complete Response Rate (CR) Based on Revised Response Criteria for Malignant Lymphoma (2007)(Revised RC)
- (and 9 more...)
|
70 |
All |
20 Years to 79 Years (Adult, Senior) |
NCT01718691 |
2011002 |
|
November 2011 |
November 2013 |
November 2013 |
October 31, 2012 |
April 27, 2016 |
April 27, 2016 |
- Research site
Nagoya, Aichi, Japan - Research site
Kashiwa, Chiba, Japan - Research site
Sapporo, Hokkaido, Japan - (and 11 more...)
|
| 113 |
NCT00109967 |
Completed
Has Results |
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
- Recurrent Mantle Cell Lymphoma
|
- Biological: rituximab
- Drug: temsirolimus
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (Complete and Partial Responses) as Defined by the International Workshop Criteria
- Time to Progression
- Duration of Response
- (and 2 more...)
|
71 |
All |
18 Years and older (Adult, Senior) |
NCT00109967 |
NCI-2009-00644
N038H
U10CA025224
CDR0000425334 |
|
May 2005 |
September 2009 |
March 2012 |
May 4, 2005 |
April 17, 2014 |
January 22, 2014 |
- Mobile Infirmary Medical Center
Mobile, Alabama, United States - The Medical Center of Aurora
Aurora, Colorado, United States - Boulder Community Hospital
Boulder, Colorado, United States - (and 192 more...)
|
| 114 |
NCT03425591 |
Recruiting |
A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice |
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Mantle-Cell
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Progressive-Free Survival (PFS)
- Overall Response Rate (ORR)
- Time to First Response
- (and 9 more...)
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT03425591 |
CR107363
54179060CAN4001 |
FIRE |
May 11, 2016 |
May 22, 2022 |
May 22, 2022 |
February 7, 2018 |
March 8, 2018 |
|
|
| 115 |
NCT02242097 |
Recruiting |
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma |
- Contiguous Stage II Mantle Cell Lymphoma
- Noncontiguous Stage II Mantle Cell Lymphoma
- Stage I Mantle Cell Lymphoma
- (and 2 more...)
|
- Drug: ibrutinib
- Other: laboratory biomarker analysis
|
Interventional |
Phase 2 |
- Northwestern University
- Janssen Scientific Affairs, LLC
- National Cancer Institute (NCI)
|
Other / Industry / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the progression-free survival (PFS) rate after 2 years
- Incidence of adverse events, defined according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.0
- Rate of conversion from Partial Response (PR) to Complete Response (CR)
- Determine median Overall Survival (OS) after 4 years
|
36 |
All |
18 Years and older (Adult, Senior) |
NCT02242097 |
NU 14H06
NCI-2014-01777
PCI-32765MCL2003
STU00098385
P30CA060553 |
|
January 2015 |
June 2018 |
January 2019 |
September 16, 2014 |
March 1, 2018 |
|
- Northwestern University
Chicago, Illinois, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - Tufts University
Medford, Massachusetts, United States - (and 2 more...)
|
| 116 |
NCT01460602 |
Terminated |
Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma |
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Mantle Cell Lymphoma
|
- Drug: MTD of Velcade, Nipent and Rituxan established in Part 1
|
Interventional |
Phase 1
Phase 2 |
- Louisiana State University Health Sciences Center Shreveport
- Millennium Pharmaceuticals, Inc.
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- CR following treatment with VELCADE(bortezomib)/Nipent(pentostatin/Rituxan (rituximab)(VNR) in subjects with follicular lymphoma(FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL)relapsed or refractory after at least 1 prior therapy
- ORR following treatment with VELCADE(bortezomib)/Nipent(pentostatin/Rituxan (rituximab)(VNR) in subjects with follicular lymphoma(FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL)relapsed or refractory after at least 1 prior therapy
- Maximum Tolerated Dose
- Rate of progression of disease
|
30 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT01460602 |
X05266 |
|
May 2010 |
October 2014 |
October 2014 |
October 27, 2011 |
October 27, 2011 |
|
- LSU - Shreveport Health Sciences Center, Feist-Weiller Cancer Center
Shreveport, Louisiana, United States
|
| 117 |
NCT00656084 |
Completed
Has Results |
Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell |
- Relapsed or Refractory Mantle Cell Lymphoma (MCL)
|
- Drug: gemcitabine
- Drug: mitoxantrone
- Drug: rituximab
|
Interventional |
Phase 2 |
- US Oncology Research
- Eli Lilly and Company
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (CR + PR)
- Duration of Response
- Overall Survival (OS) Rate at 1 Year
- Progression-free Survival Rate at 1 Year.
|
16 |
All |
18 Years and older (Adult, Senior) |
NCT00656084 |
04-026 |
|
December 2004 |
January 2007 |
January 2008 |
April 10, 2008 |
November 3, 2016 |
November 3, 2016 |
|
| 118 |
NCT00871546 |
Terminated |
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715) |
- Lymphoma, Mantle-Cell
- Leukemia, Lymphocytic, Chronic, B-Cell
|
- Drug: SCH 727965
- Drug: Bortezomib
- Biological: Alemtuzumab
|
Interventional |
Phase 2 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate of initial treatment with SCH 727965 in subjects with MCL or B-CLL.
- Response rate in subjects treated with SCH 727965 after disease progression on comparator drug.
- Time to disease progression for initial treatment with SCH 727965.
- (and 3 more...)
|
8 |
All |
18 Years and older (Adult, Senior) |
NCT00871546 |
P04715 |
|
March 2009 |
December 2010 |
December 2010 |
March 30, 2009 |
August 7, 2015 |
|
|
| 119 |
NCT01527149 |
Active, not recruiting |
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma |
- Stage I Mantle Cell Lymphoma
- Stage II Contiguous Mantle Cell Lymphoma
- Stage II Non-Contiguous Mantle Cell Lymphoma
- (and 2 more...)
|
- Procedure: Autologous Hematopoietic Stem Cell Transplantation
- Drug: Cyclophosphamide
- Drug: Cytarabine
- (and 6 more...)
|
Interventional |
Phase 2 |
- Roswell Park Cancer Institute
- National Cancer Institute (NCI)
- National Comprehensive Cancer Network
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients experiencing a complete response
- Ability of the induction and consolidation therapy to get 70% of patients to autologous stem cell transplantation
- Change in surface CD20 levels, Ki67, and additional cytogenetic abnormalities
- (and 8 more...)
|
37 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01527149 |
I 201611
NCI-2011-03562
P30CA016056 |
|
December 6, 2011 |
October 5, 2020 |
October 5, 2021 |
February 6, 2012 |
January 29, 2018 |
|
- Roswell Park Cancer Institute
Buffalo, New York, United States - Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, United States
|
| 120 |
NCT00433537 |
Completed
Has Results |
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma |
- Contiguous Stage II Mantle Cell Lymphoma
- Noncontiguous Stage II Mantle Cell Lymphoma
- Stage I Mantle Cell Lymphoma
- (and 2 more...)
|
- Drug: bortezomib
- Biological: rituximab
- Drug: cyclophosphamide
- (and 6 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response (CR) Rate
- 2-year Progression-free Survival (PFS)
- 3-year Overall Survival (OS)
|
77 |
All |
18 Years and older (Adult, Senior) |
NCT00433537 |
NCI-2012-02966
E1405
U10CA021115 |
|
May 2007 |
June 2013 |
June 2013 |
February 12, 2007 |
October 30, 2014 |
October 30, 2014 |
- Eastern Cooperative Oncology Group
Boston, Massachusetts, United States
|
| 121 |
NCT02489123 |
Recruiting |
Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma |
- Ann Arbor Stage I Mantle Cell Lymphoma
- Ann Arbor Stage II Mantle Cell Lymphoma
- Ann Arbor Stage III Mantle Cell Lymphoma
- (and 3 more...)
|
- Drug: Enzalutamide
- Other: Laboratory Biomarker Analysis
|
Interventional |
Not Applicable |
- University of Washington
- National Cancer Institute (NCI)
- National Comprehensive Cancer Network
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Best overall response rate (ORR) including complete response (CR) and partial response (PR) as measured by standard criteria
- Time to treatment failure
- Progression-free survival
- (and 3 more...)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT02489123 |
9340
NCI-2015-00947
P30CA015704 |
|
August 11, 2015 |
July 1, 2023 |
|
July 2, 2015 |
March 29, 2018 |
|
- Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
|
| 122 |
NCT00003502 |
Withdrawn |
Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma |
- Contiguous Stage II Mantle Cell Lymphoma
- Noncontiguous Stage II Mantle Cell Lymphoma
- Stage III Mantle Cell Lymphoma
- (and 2 more...)
|
- Drug: antineoplaston A10
- Drug: antineoplaston AS2-1
- Procedure: alternative product therapy
- (and 5 more...)
|
Interventional |
Phase 2 |
- Burzynski Research Institute
- National Cancer Institute (NCI)
|
Other |
- Primary Purpose: Treatment
|
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT00003502 |
BC-LY-9
CDR0000066542 |
|
|
|
|
January 27, 2003 |
July 10, 2013 |
|
- Burzynski Clinic
Houston, Texas, United States
|
| 123 |
NCT00958256 |
Completed
Has Results |
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab |
- Mantle Cell Lymphoma
- Lymphoma
|
- Drug: Bortezomib
- Drug: Rituximab
- Drug: Cyclophosphamide
- (and 2 more...)
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Millennium Pharmaceuticals, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
22 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT00958256 |
2009-0057
X05290
NCI-2009-01577 |
|
August 2009 |
March 2014 |
March 2014 |
August 13, 2009 |
April 13, 2015 |
April 13, 2015 |
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 124 |
NCT00081874 |
Completed |
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma |
- Leukemia
- Mantle Cell Lymphoma
- Myelofibrosis
|
|
Interventional |
Phase 1
Phase 2 |
- M.D. Anderson Cancer Center
- Novartis
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD)
- Objective Response Rate (ORR)
|
29 |
All |
Child, Adult, Senior |
NCT00081874 |
2003-0948 |
|
April 2004 |
September 2006 |
September 2006 |
April 27, 2004 |
March 21, 2012 |
|
- M.D. Anderson Cancer Center
Houston, Texas, United States
|
| 125 |
NCT02413489 |
Terminated |
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma |
- Lymphoma, Mantle-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Follicular
|
|
Interventional |
Phase 2 |
- Janssen Research & Development, LLC
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Overall response rate (ORR)
- Duration of response (DoR)
- Progression Free Survival (PFS)
- (and 2 more...)
|
42 |
All |
18 Years and older (Adult, Senior) |
NCT02413489 |
CR106660
54767414LYM2001
2014-005299-26 |
|
September 2, 2015 |
June 1, 2017 |
June 1, 2017 |
April 10, 2015 |
July 2, 2017 |
|
- Duarte, California, United States
- Fountain Valley, California, United States
- Jacksonville, Florida, United States
- (and 32 more...)
|
| 126 |
NCT01267812 |
Active, not recruiting |
Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation |
- Contiguous Stage II Mantle Cell Lymphoma
- Noncontiguous Stage II Mantle Cell Lymphoma
- Recurrent Mantle Cell Lymphoma
- (and 3 more...)
|
- Drug: bortezomib
- Biological: rituximab
- Other: laboratory biomarker analysis
- (and 7 more...)
|
Interventional |
Phase 2 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease-free survival rate
- Overall survival
- Time to treatment failure
- Toxicities of bortezomib and rituximab treatment, graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0
|
36 |
All |
19 Years and older (Adult, Senior) |
NCT01267812 |
10137
NCI-2010-02343 |
|
August 26, 2011 |
July 2018 |
July 2018 |
December 29, 2010 |
March 7, 2018 |
|
- City of Hope Medical Center
Duarte, California, United States - Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States
|
| 127 |
NCT03229382 |
Not yet recruiting |
Evaluation of Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse After First Line Immunochemotherapy With Autologous Stem Cell |
|
|
Interventional |
Phase 2 |
- Polish Lymphoma Research Group
- Roche Pharma AG
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MRD negativity defined as a MRD level
- Progression-free survival (PFS)
- Time to molecular relapse
- (and 5 more...)
|
60 |
All |
18 Years to 65 Years (Adult) |
NCT03229382 |
ML29157
2015-005439-41 |
OPERA PLRG-10 |
July 2017 |
July 2023 |
November 2024 |
July 25, 2017 |
July 31, 2017 |
|
- Centrum Onkologii - Instytut im. Marii Skłodowskiej- Curie Klinika Nowotworów Układu Chłonnego
Warszawa, Poland - Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocławiu Katedra i Klinika Hematologii, Nowotworów Krwi i Transplantacji Szpiku Uniwersytetu Medycznego
Wrocław, Poland
|
| 128 |
NCT02419560 |
Recruiting |
Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL |
- Lymphoma, Mantle-Cell
- Recurrent Lymphoma, Mantle-Cell
|
- Drug: ABT-199 and Ibrutinib Combination
|
Interventional |
Phase 1 |
- Craig Portell, MD
- AbbVie
- University of Virginia
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Dose Limiting Toxicities
- Incidence and Severity of Adverse Events
- Overall Response Rate
- (and 3 more...)
|
28 |
All |
18 Years and older (Adult, Senior) |
NCT02419560 |
17983
ABT199-MCL-UVA-001 |
|
April 2015 |
August 2018 |
December 2018 |
April 17, 2015 |
October 26, 2017 |
|
- City of Hope
Duarte, California, United States - Winship Cancer Institute, Emory University
Atlanta, Georgia, United States - Washington University School of Medicine
Saint Louis, Missouri, United States - University of Virginia
Charlottesville, Virginia, United States
|
| 129 |
NCT00261612 |
Unknown † |
Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma |
|
- Drug: bortezomib
- Drug: rituximab
- Drug: dexamethasone
- Procedure: treatment protocol
|
Interventional |
Phase 2 |
- Medical University of Vienna
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- response rate
- safety
- progression free survival
- overall survival
|
16 |
All |
19 Years to 75 Years (Adult, Senior) |
NCT00261612 |
2004-002150-64
MCL 03 |
|
January 2005 |
|
January 2007 |
December 5, 2005 |
October 18, 2006 |
|
- Medical University Vienna, Dept. of Medicine I, Clinical Division of Oncology
Vienna, Austria
|
| 130 |
NCT00921414 |
Completed |
Mantel Cell Lymphoma Efficacy of Rituximab Maintenance |
|
- Drug: Rituximab
- Other: Watch and wait
|
Interventional |
Phase 3 |
- French Innovative Leukemia Organisation
- Lymphoma Study Association
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- event-free survival (EFS) post Rituximab maintenance therapy
- duration of PFS of the entire group of patients.
- duration of OS of the entire group of patients
- complete, partial and overall response rate after induction with R-DHAP and after ASCT.
|
299 |
All |
18 Years to 65 Years (Adult) |
NCT00921414 |
Manteau 2007 SJ "LYMA" |
|
September 2008 |
September 2008 |
February 2017 |
June 16, 2009 |
February 15, 2017 |
|
- Regional University Hospital
Nantes, France
|
| 131 |
NCT00720447 |
Unknown † |
Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma |
|
- Biological: alemtuzumab
- Biological: donor lymphocytes
- Drug: carmustine
- (and 5 more...)
|
Interventional |
Phase 2 |
- Cancer Research UK
- National Cancer Institute (NCI)
|
Other |
- Allocation: Non-Randomized
- Primary Purpose: Treatment
|
- Progression-free survival
- Overall survival
- Toxicity
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT00720447 |
UCL-BRD-07-137
CDR0000597903
EUDRACT 2007-003081-18 |
|
November 2008 |
November 2010 |
|
July 22, 2008 |
August 2, 2013 |
|
|
| 132 |
NCT00377052 |
Completed |
Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma |
|
- Drug: bortezomib
- Drug: gemcitabine hydrochloride
|
Interventional |
Phase 2 |
- NCIC Clinical Trials Group
- Canadian Cancer Trials Group
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective tumor response (overall response rate with 95% confidence interval)
- Time to progression at median time
- Duration of response (median and range)
- Rate of stable disease and progressive disease
|
29 |
All |
18 Years and older (Adult, Senior) |
NCT00377052 |
I172
CAN-NCIC-IND172
ORTHO-CAN-NCIC-IND172
CDR0000493021 |
|
June 2006 |
November 2009 |
June 2011 |
September 15, 2006 |
June 22, 2011 |
|
- Cross Cancer Institute
Edmonton, Alberta, Canada - BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada - CancerCare Manitoba
Winnipeg, Manitoba, Canada - (and 8 more...)
|
| 133 |
NCT00513955 |
Completed |
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma |
|
- Drug: bortezomib
- Drug: cyclophosphamide
- Drug: doxorubicin hydrochloride
- (and 4 more...)
|
Interventional |
Phase 2 |
- University Hospital Plymouth NHS Trust
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease progression
- Unacceptable toxicity or tolerability as assessed by NCI CTCAE v3.0
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT00513955 |
CDR0000559820
NCRN-Ply-26s
EU-20747
ISRCTN200600609024 |
|
June 2006 |
October 2014 |
October 2014 |
August 9, 2007 |
November 5, 2014 |
|
- Basingstoke and North Hampshire NHS Foundation Trust
Basingstoke, England, United Kingdom - Good Hope Hospital
Birmingham, England, United Kingdom - Birmingham Heartlands Hospital
Birmingham, England, United Kingdom - (and 22 more...)
|
| 134 |
NCT00209209 |
Active, not recruiting |
Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL |
|
- Drug: Rituximab
- Drug: Cyclophosphamide
- Drug: Doxorubicin
- (and 9 more...)
|
Interventional |
Phase 3 |
- European Mantle Cell Lymphoma Network
- German Low Grade Lymphoma Study Group
- Lymphoma Study Association
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- First randomisation: Reduction of lymphoma mass measured by the complete remission (CR) rate
- Second randomisation: progression-free survival after end of initial chemotherapy
- Survival after registration / first randomisation / second randomisation
- (and 5 more...)
|
570 |
All |
60 Years and older (Adult, Senior) |
NCT00209209 |
MCL2004-1 |
MCLelderly |
January 14, 2004 |
December 2018 |
December 2018 |
September 21, 2005 |
March 7, 2017 |
|
- General University Hospital, 1St Department of Medicine
Praha, Czech Republic - Nordic Lymphoma Group
Copenhagen, Denmark - Groupe D´Etudes des Lymphomes De l´Adulte (GELA)
Paris, France - (and 4 more...)
|
| 135 |
NCT01456351 |
Completed |
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab |
- Non-Hodgkin's Lymphoma
- Mantle Cell Lymphoma
|
- Drug: Bendamustine plus Rituximab
- Drug: Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event Free Survival
- Remission Rates
|
230 |
All |
18 Years and older (Adult, Senior) |
NCT01456351 |
NHL 2-2003 |
|
September 2003 |
August 2010 |
December 2010 |
October 20, 2011 |
February 12, 2013 |
|
- StiL Head Office; Justus-Liebig-University
Giessen, Germany
|
| 136 |
NCT00737529 |
Completed
Has Results |
A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial |
|
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With an Overall Response
- Duration of Response (DoR)
- Time to Response (TTR)
- (and 8 more...)
|
134 |
All |
18 Years and older (Adult, Senior) |
NCT00737529 |
CC-5013-MCL-001 |
EMERGE |
December 22, 2008 |
October 15, 2012 |
November 8, 2017 |
August 19, 2008 |
December 5, 2017 |
September 9, 2013 |
- University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - UCSD Moores Cancer Center
La Jolla, California, United States - Loma Linda University Medical Center
Loma Linda, California, United States - (and 67 more...)
|
| 137 |
NCT00490529 |
Completed |
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL |
|
- Biological: CpG-MCL vaccine, primed T-cells
- Procedure: Autologous peripheral blood stem cell transplantation
- Procedure: CT scan
- (and 3 more...)
|
Interventional |
Phase 2 |
- Ronald Levy
- National Institutes of Health (NIH)
- Stanford University
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary endpoint of the trial is freedom from molecular residual disease (MRD) at the landmark of one-year post-transplant.
- Secondary objectives are Time To Clinical Progression (TTP), and evaluation of anti-tumor immune responses after vaccination, and after immunotransplant. progression-free survival.
|
61 |
All |
21 Years to 70 Years (Adult, Senior) |
NCT00490529 |
LYMNHL0040-BMT212
IRB-05089
96940 |
|
August 2009 |
December 14, 2017 |
December 14, 2017 |
June 22, 2007 |
January 23, 2018 |
|
- Stanford University Medical Center
Stanford, California, United States
|
| 138 |
NCT02603445 |
Active, not recruiting |
Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL |
- Follicular Lymphoma, Mantle Cell Lymphoma
|
- Drug: BCL201
- Drug: Idelalisib
|
Interventional |
Phase 1 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with adverse events (AEs)
- Incidence rate of dose limiting toxicities (DLTs)
- Exposure to BCL201 and idelalisib as measured by AUC0-24h at C1D15
- (and 9 more...)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT02603445 |
CBCL201X2102C |
|
November 16, 2015 |
June 29, 2018 |
June 29, 2018 |
November 11, 2015 |
April 23, 2018 |
|
- Novartis Investigative Site
New York, New York, United States - Novartis Investigative Site
Houston, Texas, United States - Novartis Investigative Site
Salzburg, Austria - (and 4 more...)
|
| 139 |
NCT00700258 |
Recruiting |
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] |
- Carcinoma, Renal Cell, Advanced
- Lymphoma, Mantle-Cell
- Gastrointestinal Stroma Tumors
|
- Drug: Temsirolimus
- Drug: Sunitinib
- Drug: Axitinib
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Safety: absolute and relative incidence of adverse events
- Efficacy: best response, progression-free survival, overall survival
- Safety: absolute and relative incidence of therapy interruption
|
1600 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT00700258 |
3066K1-4407
B1771009 |
STAR-TOR |
January 2013 |
December 2023 |
December 2023 |
June 18, 2008 |
January 9, 2018 |
|
- Dr. med. Harald Held
Neumuenster, Schleswig-holstein, Germany - Dr. med. Hans Wilhelm Duebbers
Ahaus, Germany - Dr. Ludwig Fischer von Weikersthal
Amberg, Germany - (and 64 more...)
|
| 140 |
NCT00003541 |
Completed |
Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma |
|
- Biological: filgrastim
- Drug: CHOP regimen
- Drug: carboplatin
- (and 8 more...)
|
Interventional |
Phase 1
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
24 |
All |
18 Years and older (Adult, Senior) |
NCT00003541 |
98-045
CDR0000066595
NCI-H98-0021 |
|
June 1998 |
July 2006 |
July 2006 |
January 23, 2004 |
June 24, 2013 |
|
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
|
| 141 |
NCT00151281 |
Completed
Has Results |
Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma |
|
- Drug: PEPC
- Drug: Thalidomide
- Drug: Rituximab
|
Interventional |
Phase 2 |
- Weill Medical College of Cornell University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival and Progression Free Survival
- Asses the Toxicity Profiles
- Dynamic Levels of Plasma VEGF
- The Quality of Life (QoL) of Patients Receiving RT-PEPC Treatment
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT00151281 |
047080073974 |
|
November 2004 |
December 2009 |
April 7, 2011 |
September 8, 2005 |
September 12, 2017 |
September 12, 2017 |
- Weill Medical College of Cornell University
New York, New York, United States
|
| 142 |
NCT02267590 |
Unknown † |
Tissue Collection for Biomarkers Determining Resistance to Ibrutinib |
- Mantle Cell Lymphoma
- Chronic Lymphocytic Leukaemia
|
|
Observational |
|
- Royal Marsden NHS Foundation Trust
- University Hospital Plymouth NHS Trust
- Cambridge University Hospitals NHS Foundation Trust
|
Other |
- Time Perspective: Prospective
|
- Total number of MCL and CLL patient samples collected, both pre-treatment and at progression.
|
120 |
All |
Child, Adult, Senior |
NCT02267590 |
CCR4187 |
CLARITY |
October 2014 |
October 2016 |
October 2016 |
October 17, 2014 |
October 17, 2014 |
|
- The Royal Marsden NHS Foundation Trust
Sutton, Surrey, United Kingdom
|
| 143 |
NCT00016887 |
Unknown † |
Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma |
|
- Biological: filgrastim
- Biological: recombinant interferon alfa
- Drug: carmustine
- (and 8 more...)
|
Interventional |
Phase 3 |
- German Low Grade Lymphoma Study Group
- European Organisation for Research and Treatment of Cancer - EORTC
- Gruppo Italiano Studio Linfomi
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Primary Purpose: Treatment
|
|
|
All |
18 Years to 65 Years (Adult) |
NCT00016887 |
CDR0000068609
GER-LGLSG-INTERGROUP-20995
EORTC-20995
GELA-INTERGROUP-20995
GISL-INTERGROUP-20995 |
|
December 2000 |
|
|
January 27, 2003 |
September 17, 2013 |
|
- AZ Sint-Jan
Brugge, Belgium - Ospedale Civile Alessandria
Alessandria, Italy
|
| 144 |
NCT01170052 |
Withdrawn |
Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) |
|
- Drug: Temsirolimus
- Drug: Bendamustine
|
Interventional |
Phase 1
Phase 2 |
- Charite University, Berlin, Germany
- Wyeth is now a wholly owned subsidiary of Pfizer
- Mundipharma K.K.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase I: Dose-finding
- Phase II: Response Rate (Overall response rate, complete and partial response)
- Progression free survival
- Safety and Tolerability of Temsirolimus and Bendamustine Combination Therapy
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT01170052 |
EudraCT-No.: 2009-014844-13 |
|
May 2010 |
April 2012 |
April 2014 |
July 27, 2010 |
March 16, 2011 |
|
- Dept. of Hematology and Oncology, Charité, Campus Charité Mitte
Berlin, Germany - Dept. of Hematology and Oncology, Charité, Campus Benjamin Franklin
Berlin, Germany - Dept. of Hematology and Oncology, Charité, Campus Virchow Klinikum Charité
Berlin, Germany
|
| 145 |
NCT00117988 |
Completed
Has Results |
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma |
- Anaplastic Large Cell Lymphoma
- Recurrent Adult Hodgkin Lymphoma
- Recurrent Mantle Cell Lymphoma
|
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Patients With Response
|
22 |
All |
16 Years and older (Child, Adult, Senior) |
NCT00117988 |
NCI-2009-00101
CDR0000433593
2004-0792
6936
P30CA016672
R21CA117070 |
|
February 2005 |
April 2010 |
April 2010 |
July 11, 2005 |
May 30, 2014 |
May 30, 2011 |
- M D Anderson Cancer Center
Houston, Texas, United States
|
| 146 |
NCT00004231 |
Completed |
Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma |
|
- Biological: aldesleukin
- Biological: filgrastim
- Biological: recombinant interferon alfa
- (and 12 more...)
|
Interventional |
Phase 2 |
- Northwestern University
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
All |
18 Years and older (Adult, Senior) |
NCT00004231 |
NU 96H3
NU-96H3
NCI-G99-1659 |
|
October 1999 |
August 2006 |
August 2006 |
January 27, 2003 |
June 6, 2012 |
|
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University
Chicago, Illinois, United States
|
| 147 |
NCT03235544 |
Recruiting |
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) |
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate
- Duration of response
- Complete response rate
- (and 4 more...)
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT03235544 |
INCB 50465-205 (CITADEL-205) |
|
October 5, 2017 |
July 2020 |
May 2021 |
August 1, 2017 |
March 27, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - St Joseph Heritage Healthcare
Orange, California, United States - USOR - Rocky Mountain Cancer Centers
Denver, Colorado, United States - (and 98 more...)
|
| 148 |
NCT00703664 |
Completed |
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma |
- Recurrent Mantle Cell Lymphoma
- Recurrent Non-Hodgkin Lymphoma
|
- Drug: Bortezomib
- Other: Laboratory Biomarker Analysis
- Drug: Vorinostat
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rates (complete and partial response) assessed according to the Revised Response Criteria for Malignant Lymphoma
|
65 |
All |
18 Years and older (Adult, Senior) |
NCT00703664 |
NCI-2009-00275
CDR0000598308
MCC-8064
8064
N01CM00071
N01CM00100
N01CM62201
N01CM62204
N01CM62208
P30CA076292 |
|
July 9, 2008 |
December 1, 2017 |
|
June 23, 2008 |
March 27, 2018 |
|
- Moffitt Cancer Center
Tampa, Florida, United States - Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States - Northwestern University
Chicago, Illinois, United States - (and 9 more...)
|
| 149 |
NCT01397591 |
Terminated
Has Results |
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma |
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- (and 2 more...)
|
- Biological: Ofatumumab
- Drug: Bortezomib
|
Interventional |
Phase 2 |
- OHSU Knight Cancer Institute
- National Cancer Institute (NCI)
- Millennium Pharmaceuticals, Inc.
- GlaxoSmithKline
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate of Ofatumumab in Combination With Bortezomib in Patients With Relapsed CD20+ (Cluster of DIfferentiation Antigen 20) Diffuse Large B Cell Lymphoma, Follicular Lymphoma, or Mantle Cell Lymphoma
- Overall Survival
- Progression Free Survival
- (and 2 more...)
|
3 |
All |
18 Years and older (Adult, Senior) |
NCT01397591 |
IRB00007042
NCI-2011-01032
OFT113735 |
|
October 2011 |
May 2013 |
July 2013 |
July 19, 2011 |
July 30, 2014 |
July 30, 2014 |
- OHSU Knight Cancer Institute
Portland, Oregon, United States
|
| 150 |
NCT00740415 |
Completed |
Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma |
|
- Biological: rituximab
- Drug: bortezomib
- Drug: dexamethasone
- Drug: Bendamustine
|
Interventional |
Phase 2 |
- French Innovative Leukemia Organisation
- Janssen, LP
- Mundipharma Pte Ltd.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate after 4 courses of therapy
|
39 |
All |
65 Years to 80 Years (Adult, Senior) |
NCT00740415 |
CDR0000589544
-MANTEAU-2010-SA |
ManteauRiBVD |
June 2007 |
May 2011 |
August 2015 |
August 25, 2008 |
March 16, 2016 |
|
- CHU de Grenoble - Hopital Michallon
Grenoble, France
|
Create an RSS feed from your search for:
Download the search results for: